Neogenomics (NEO) risk factors, FY2024 10-K

Risks Relating to Our Business

1. 01We are dependent on key personnel and need to hire additional qualified personnel in order for our business to succeed
2. 02If we are unable to keep pace with the rapid scientific and technological change characteristic to our industry, or to develop, or acquire licenses for, new or improved testing technologies, our competitive position, business, results of operations, and financial condition could be harmed
3. 03We face the risk of capacity constraints, which could have a material adverse effect on our business, results of operations, and financial condition
4. 04Increased competition, including price competition, could have a material adverse impact on our net revenues and profitability
5. 05We expect to make significant investments in the development of new genetic tests and other future products. New product development and commercialization involve a lengthy and complex process and we may be unable to develop or commercialize new products on a timely basis, or at all
6. 06Ethical, legal and social concerns related to the use of genetic information could reduce demand for our tests
7. 07The potential loss or delay of our material client contracts could adversely affect our results
8. 08We may become involved in litigation, and our insurance may not sufficiently cover all claims brought against us, which will increase our expenses and may adversely affect our business and results of operations
9. 09We may be unable to obtain, maintain or enforce our intellectual property rights and may be subject to intellectual property litigation that could adversely impact our business
10. 10Our involvement with clinical trials and research services creates a risk of liability
11. 11Our investments in marketable securities are subject to certain risks which could affect our overall financial condition, results of operations, or cash flows
12. 12Other manufacturers may discontinue or recall testing products used in our business
13. 13We depend substantially upon third parties for payment of services, which reliance could have a material adverse effect on our cash flows and results of operations
14. 14If our facilities become damaged or inoperable due to disasters, power loss, break-ins or similar events, we may be unable to continue our operations or our services could be interrupted or delayed, which could have a material adverse effect on our business, results of operations, and financial condition
15. 15Performance issues, service interruptions, or price increases by our shipping carrier could adversely affect our business, results of operations, and financial condition, and harm our reputation and ability to provide our specialized clinical services on a timely basis
16. 16We use biological and hazardous materials that require considerable expertise and expense for handling, storage, or disposal and may result in claims against us

Risks Related to Our Common Stock and Indebtedness

1. 17The price of our common stock has, and may continue to, fluctuate significantly
2. 18Servicing our Convertible Notes requires a significant amount of cash. We may not have sufficient cash flow from our business to pay our obligations under the Convertible Notes, which could adversely affect our financial condition and operating results
3. 19We may not have the ability to raise the funds necessary to settle conversions of the Convertible Notes in cash or to repurchase the Convertible Notes upon a fundamental change, and our future debt may contain limitations on our ability to pay cash upon conversion or repurchase of the Convertible Notes
4. 20The capped call transactions may affect the value of the 2028 Convertible Notes and our common stock
5. 21Conversion of the Convertible Notes may dilute the ownership interest of existing stockholders or may otherwise depress the price of our common stock

Risks Relating to Government Regulation and Reimbursement

1. 22If the FDA were to begin to enforce regulation of Laboratory Developed Tests it could require us to conduct additional clinical trials, result in increased costs or delays, or we could fail to obtain necessary regulatory approvals, all of which could harm our business
2. 23Healthcare reform efforts may impact our business and the pricing we receive for our services
3. 24We face efforts by government payers to reduce utilization as well as reimbursement for laboratory testing services. Changes in governmental reimbursement may result from statutory and regulatory changes, prospective and/or retroactive rate adjustments, administrative rulings, and other policy changes
4. 25engineering controls such as safety needles, if found to be effective at reducing the risk of needlestick injuries in the workplace
5. 26Our net revenue will be diminished if payers do not adequately cover or reimburse our services
6. 27Our operations are subject to strict laws prohibiting fraudulent billing and other abuse, and our failure to comply with such laws could result in substantial penalties, including exclusion from participation in Medicare, Medicaid, and other governmental payer programs
7. 28The failure to comply with fraud and abuse laws, including physician self-referral laws and anti-kickback laws, may subject us to liability, penalties, or limitation of operations
8. 29Failure to comply with federal, state and international laws related to privacy and security could result in fines, penalties, and damage to the Company’s reputation with clients and could have a material adverse effect upon the Company’s business
9. 30We may not be able to implement our business strategy, which could impair our ability to continue operations
10. 31We may be unable to realize estimated benefits from our cost reduction and restructuring efforts and our profitability may be hurt or our business might otherwise be adversely affected
11. 32If we are unable to successfully integrate future acquisitions with our business, the anticipated benefits of such transaction may not be realized and our business, financial conditions, results of operations and cash flows may be adversely affected
12. 33If goodwill and intangible assets that we recorded in connection with our acquisitions become impaired, we may have to take significant charges against earnings
13. 34We may incur greater costs than anticipated in connection with implementing our business strategy, which could result in sustained losses
14. 35We may face fluctuations in our results of operations and we are subject to seasonality in our business which could negatively affect our business operations
15. 36The steps we have taken to protect our intellectual property and proprietary rights may not be adequate, which could result in infringement or misappropriation by third parties
16. 37We may be subject to claims that we or our employees have wrongfully used or disclosed alleged trade secrets